Skip to main content
Apt Medical Inc. logo

Apt Medical Inc. — Investor Relations & Filings

Ticker · 688617 ISIN · CNE100004C45 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 660 across all filing types
Latest filing 2026-04-14 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688617

About Apt Medical Inc.

https://www.aptmed.com/

Apt Medical Inc. is a specialized developer and manufacturer of advanced medical devices for minimally invasive vascular interventions. The company focuses on the fields of electrophysiology, interventional cardiology, and peripheral vascular procedures. Its product portfolio includes diagnostic and ablation catheters, steerable sheaths, guide wires, microcatheters, and balloon catheters designed for complex cardiovascular treatments. Apt Medical emphasizes research and development to provide high-precision tools for clinicians, aiming to improve procedural outcomes in the treatment of cardiac arrhythmias and vascular diseases. The company serves a global market, providing integrated solutions for interventional procedures through a commitment to technological innovation and quality manufacturing standards.

Recent filings

Filing Released Lang Actions
关于向2026年限制性股票激励计划激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Huitai Medical Equipment Co., Ltd. regarding the initial grant of restricted stock under its 2026 restricted stock incentive plan. It includes specifics such as the grant date, number of shares granted, grant price, eligibility criteria, vesting schedules, accounting treatment, and legal opinions. The content focuses on the company's equity incentive plan and the granting of restricted shares to employees and management. This is not a financial report, earnings release, or management discussion, but rather a formal announcement about a capital/financing activity related to stock-based compensation. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length and detail confirm it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2026-04-14 Chinese
北京市嘉源律师事务所关于深圳惠泰医疗器械股份有限公司2026年限制性股票激励计划首次授予事项的法律意见书
Regulatory Filings Classification · 84% confidence The document is a legal opinion letter (“法律意见书”) issued by an external law firm concerning the first grant of a 2026 restricted stock incentive plan. It does not present any financial statements, quarterly or annual results, governance structure overview, or proxy materials; nor is it a simple announcement of a report’s publication. Instead, it is a compliance‐related legal attestation required for the stock incentive plan. Under the classification rules, an officer certification or external counsel opinion letter that does not itself contain substantive financial data or constitute one of the defined report types falls into the “Regulatory Filings” (RNS) category as a fallback for miscellaneous compliance documents.
2026-04-14 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a formal announcement of the 2025 Annual Shareholders’ Meeting resolutions, detailing each agenda item and its vote counts and percentages. It reports the results of shareholder voting, specifying the number of votes for, against, and abstentions, and summarizes meeting attendance and legal compliance. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-14 Chinese
第三届董事会第五次会议决议公告
Regulatory Filings Classification · 72% confidence The document is a public announcement of the board of directors’ resolution at the third board meeting of Shenzhen Huitai Medical. It contains no executive changes (so not MANG), no shareholder vote results (DVA is for AGMs/EGMs), no financial report, no proxy materials, no dividend, no M&A, etc. It is a regulatory announcement of a board resolution approving the initial grant of restricted shares. Since there is no more specific category, it falls into the general Regulatory Filings category (RNS).
2026-04-14 Chinese
2026年限制性股票激励计划首次授予激励对象名单（首次授予日）
Share Issue/Capital Change Classification · 85% confidence The document is a formal announcement by Shenzhen Huitai Medical Devices Co., Ltd. detailing the first grant of restricted stock under its 2026 equity incentive plan, including allocations and proportions for directors, senior management, and other participants. It specifies the total number of shares to be issued and reserved under the plan. This constitutes a notification of new share issuance under an employee incentive program, which falls under the category “Share Issue/Capital Change” rather than a buyback or financing update. Therefore, the appropriate classification is SHA.
2026-04-14 Chinese
董事会薪酬与考核委员会关于公司2026年限制性股票激励计划首次授予激励对象名单（首次授予日）的核查意见
Remuneration Information Classification · 90% confidence The document is issued by the Board’s Remuneration and Assessment Committee, providing verification opinions on the first grant list under the 2026 restricted stock incentive plan. It cites relevant laws and rules governing equity incentives and confirms the grant details (number of shares, price, date). This directly pertains to executive/director compensation arrangements, fitting the Remuneration Information category (DEF 14A).
2026-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.